Undifferentiated carcinoma of liver and intrahepatic biliary tract Advocacy Hub | UniteRare

At a Glance

Live from database

Regulatory Watchboard

1 event

Sep 2021

CABOMETYX: FDA approved

Treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for Undifferentiated carcinoma of liver and intrahepatic biliary tract.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

CABOMETYX

(cabozantinib)Orphan drug

Exelixis, Inc.

12.1 Mechanism of Action In vitro biochemical and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of MET, VEGFR-...

Approved Sep 2021FDA label ↗

View full treatment details on disease page →